Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 11/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 11/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 11/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 11/20 | 1.00 |
| ▸ | TNF | P01375 | 11/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cdc-801 SCHEMBL29360102 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| Cdc-801 SCHEMBL9977552 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4637138 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL844824 | 0.93 | PDE4A (0.87) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4637167 | 0.92 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4637184 | 0.91 | PDE4A (0.84) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4637242 | 0.91 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4637688 | 0.91 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL5905221 | 0.91 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4637348 | 0.90 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 372 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803760-B2 | Methods of inducing ovulation | MERCK SERONO SA (CH) | 2010-09-28 | — | — | US | claimed |
| JP-4532115-B2 | — | — | 2010-08-25 | — | — | JP | claimed |
| US-20080293622-A1 | METHODS OF INDUCING OVULATION | MERCK SERONO SA (CH) | 2008-11-27 | — | — | US | claimed |
| EP-1468991-B1 | Imides as PDE III, PDE IV and TNF inhibitors | CELGENE CORP (US) | 2008-02-20 | — | — | EP | claimed |
| EP-1849468-A2 | Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist | Nycomed GmbH (DE) | 2007-10-31 | — | — | EP | claimed |
| US-20060148804-A1 | Pde4 inhibitors for the treatment of neoplasms of lymphoid cells | NYCOMED GMBH (DE) | 2006-07-06 | — | — | US | claimed |
| US-20060079540-A1 | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia | ALTANA PHARMA AG (DE) | 2006-04-13 | — | — | US | claimed |
| EP-1587512-A2 | PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS | ALTANA Pharma AG (DE) | 2005-10-26 | — | — | EP | claimed |
| US-6953774-B2 | Methods of inducing ovulation | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-10-11 | — | — | US | claimed |
| EP-1567136-A1 | PDE4 AND PDE3/4 INHIBITORS FOR USE IN THE TREATMENT OF CACHEXIA | ALTANA Pharma AG (DE) | 2005-08-31 | — | — | EP | claimed |
| EP-0874819-B1 | IMIDES AS PDE III, PDE IV AND TNF INHIBITORS | CELGENE CORP (US) | 2004-05-26 | — | — | EP | claimed |
| WO-2003074055-A1 | PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-09-12 | — | — | WO | claimed |
| WO-2003051344-A1 | METHODS OF INDUCING OVULATION_USING A NON-POLYPEPTIDE CAMP LEVEL MODULATOR | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-06-26 | — | — | WO | claimed |
| WO-2003039552-A1 | COMBINATION OF PDE4 OR PDE3/4 INHIBITOR AND AN ANTI-RHEUMATIC DRUG | ALTANA PHARMA AG (DE) | 2003-05-15 | — | — | WO | claimed |
| US-20030092706-A1 | Combination | NYCOMED GMBH (DE) | 2003-05-15 | — | — | US | claimed |
| WO-2003024489-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | claimed |
| US-20020103106-A1 | Methods of inducing ovulation | MERCK SERONO SA (CH) | 2002-08-01 | — | — | US | claimed |
| EP-0874819-A1 | IMIDES AS PDE III, PDE IV AND TNF INHIBITORS | CELGENE CORPORATION (US) | 1998-11-04 | — | — | EP | claimed |
| US-5728844-A | INHIBITORS OF TUMOR NECROSIS AND PHOSPHODIESTERASE | CELGENE CORPORATION (US) | 1998-03-17 | — | — | US | claimed |
| WO-1997023457-A1 | IMIDES AS PDE III, PDE IV AND TNF INHIBITORS | CELGENE CORPORATION (US) | 1997-07-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079540-A1 | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia | PDE4A, PDE12, PDE4B | PDE4A 1/4885PDE4B 3/4885PDE4C 7/4885 |
| US-20060148804-A1 | Pde4 inhibitors for the treatment of neoplasms of lymphoid cells | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
| US-20020103106-A1 | Methods of inducing ovulation | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
| US-20080293622-A1 | METHODS OF INDUCING OVULATION | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.